Antibody-Based Protection Against Dengue Virus

$73,745R01FY2016AINIH

Washington University, Saint Louis MO

Investigators

Michael S. Diamondcontact Daved H Fremont Richard J. Kuhn Michael G Rossmann

Linked publications & trials

Paper 39019010 Paper 38540792 Paper 37749080 Paper 37347462 Paper 36795561 Paper 36638211 Paper 36298768 Paper 35981935 Paper 35420472 Paper 35231399 Paper 34634945 Paper 34610295 Paper 34346770 Paper 33837721 Paper 33831142 Paper 33268494 Paper 33255202 Paper 33077712 Paper 33010224 Paper 32950933 Paper 32801077 Paper 32407709 Paper 32367055 Paper 31757867 Paper 31616920 Paper 31484074 Paper 31477918 Paper 31260518 Paper 30995506 Paper 30726740 Paper 30655513 Paper 30642974 Paper 30635356 Paper 30573745 Paper 30566864 Paper 30455471 Paper 30388054 Paper 30384472 Paper 30348794 Paper 30293866 Paper 30158602 Paper 30072692 Paper 29958768 Paper 29753210 Paper 29746837 Paper 29669275 Paper 29386359 Paper 29343577 Paper 29267925 Paper 28945244 Paper 28939807 Paper 28910635 Paper 28874392 Paper 28835505 Paper 28708997 Paper 28694387 Paper 28432975 Paper 28423319 Paper 28402153 Paper 28340344 Paper 28300075 Paper 28222903 Paper 28207910 Paper 28182948 Paper 28167751 Paper 28148840 Paper 28148798 Paper 28081442 Paper 28067914 Paper 27902933 Paper 27864552 Paper 27819683 Paper 27798603 Paper 27612415 Paper 27554037 Paper 27481466 Paper 27475895 Paper 27433842 Paper 27420797 Paper 27180225 Paper 27130436 Paper 27066744 Paper 27033547 Paper 26962217 Paper 26374123 Paper 26232221 Paper 25974180 Paper 25595803 Paper 25355881 Paper 24743696 Paper 24594604 Paper 24255124 Paper 24252771 Paper 24109224 Paper 23740974 Paper 23569243 Paper 22406169 Paper 20956322 Paper 20709295 Paper 19956725

Abstract

DESCRIPTION (provided by applicant): Dengue virus (DENV) causes dengue fever, the most prevalent arthropod-borne viral illness in humans (NIAID Category A pathogen). Globally, the four serotypes of DENV cause an estimated 100 million new cases of dengue fever and 250,000 cases of dengue hemorrhagic fever (DHF) per year. Currently, no specific therapy is available, and vaccines are still in early stages of development. Given that the most advanced tetravalent live attenuated DENV vaccine candidate showed a poor 30% overall efficacy rate in a recently published phase 2b clinical trial, there remains a pressing need for new approaches for safe, effective vaccines. In the first cycle of this R01 we developed a large panel of ~500 novel monoclonal antibodies (MAbs) against all four DENV serotypes and analyzed the structural, biophysical, and cellular mechanisms of Ab-mediated neutralization of several of them. These studies defined novel epitopes on DENV E proteins recognized by inhibitory antibodies (Abs), many of which are not solvent-accessible according to existing atomic models of the virus particle. Our studies revealed that the structure of DENV was more complex than anticipated and is likely a heterogeneous and structurally dynamic ensemble of different states, each of which may interact differentially with Ab. In this renewal application, we propose to define the spectrum of structural states sampled by the DENV virion, determine the structural basis of differential neutralization of individual DENV serotype by cross-reactive, fusion-loop specific Abs, and assess the role of anti-prM Abs in recognition and neutralization of DENV. This information will be translated into developing a novel inactivated vaccine strategy that traps DENV particles in structural states that preferentially elicit highly neutralizing Abs.

View original record on NIH RePORTER →